ATC Group: L01BC08 Decitabine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01BC08 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01B Antimetabolites
4 L01BC Pyrimidine analogues
5 L01BC08 Decitabine

Active ingredients in L01BC08

Active Ingredient Description
Decitabine

Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumour suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.

Related product monographs

Title Information Source Document Type  
DACOGEN Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Finland (FI)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.